Validair expands despite the recession
Even though the recession has bitten, Validair has expanded its business over the last 18 months with two acquisitions in the field of validation and construction packages
Based in Darlington, Diamond Scientific was acquired in February 2009, and dovetails neatly into Validair’s testing and certification arm – Validair Euro. Towards the end of last year, the other acquisition took place – that of Malvern-based Facility Monitoring Systems. With its expertise in supply, installation, servicing and calibration of continuous and compliant environmental monitoring systems, this company will fit into the Validair Projects side of the business and will enhance the scope of services offered by the Validair Group of Companies.
Validair Euro was established in 1989 as a validation test house within the contamination control industry. In early 2003 the company’s services further expanded with the creation of Validair Projects – a company dedicated to providing cleanroom design consultancy, construction and project management services.
Although Validair has always offered its services across the entire British Isles from its base in Wrotham, Kent, the acquisition of these two new companies gives ideal geographical sites in the Midlands and the North of England, for even quicker response to customers’ needs.
This was an important factor, as Validair director Steve Ward explains: 'We have always worked nationwide, but there are many potential clients who might have a perception of problems if you don’t have an office nearby.
'The other real advantage,' he continues, 'is that we add to our already extensive skill bases. Training up people to do the work is time-consuming, but having additional fully qualified personnel overnight is a massive benefit.”
The services on offer from the Validair Group of Companies are extensive: the company describes itself as a ‘one-stop shop’ in the field of clean and controlled environments.
Validair brings to the marketplace everything from feasibility studies and design to construction, testing and validation of the facility, including the installation of environmental monitoring systems as an integral part of the cleanroom or as a stand-alone system supply direct to the end user or project developer.
Commenting on the acquisitions, Ward says: 'While the country may have had to contend with a recession, we have managed to continue to build our business – the acquisition of Diamond Scientific and Facility Monitoring Systems is further evidence of our continued success.'
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Regulatory
FDA approves AstraZeneca's Breztri Aerosphere as first single-inhaler triple therapy for asthma
AstraZeneca has received FDA approval to extend Breztri Aerosphere's indication to include maintenance treatment of asthma in patients aged 12 and older, based on Phase III KALOS and LOGOS trial data showing statistically significant improvements in lung function
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results